PMC:7696151 / 61263-61541 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1769","span":{"begin":10,"end":22},"obj":"Chemical"},{"id":"1770","span":{"begin":213,"end":220},"obj":"Chemical"},{"id":"1786","span":{"begin":38,"end":46},"obj":"Disease"}],"attributes":[{"id":"A1769","pred":"tao:has_database_id","subj":"1769","obj":"MESH:D000077205"},{"id":"A1770","pred":"tao:has_database_id","subj":"1770","obj":"MESH:D005947"},{"id":"A1786","pred":"tao:has_database_id","subj":"1786","obj":"MESH:D003920"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"/day) and pioglitazone, a common anti-diabetic drug, in the control of glycemic and lipidic profiles. No statistically significant differences emerged between the two medicines in terms of glycated hemoglobin and glucose levels, although both drugs produced an improvement in gl"}